SGNLVA-002: Single arm, open label, phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancer

被引：0

作者：

Boni, V. ^{[1
]}

Alemany, C. ^{[2
]}

Meisel, J. L. ^{[3
]}

Sinha, R. ^{[4
]}

Sterrenberg, D. ^{[5
]}

Tkaczuk, K. H. R. ^{[6
]}

Wang, Y. ^{[7
]}

Wang, Z. ^{[8
]}

Han, H. S. ^{[9
]}

机构：

[1] Hosp Univ HM Sanchinarro, Ctr Integral Oncol Clara Campal, Madrid, Spain

[2] Canc Inst Florida, AdventHlth Med Grp, Orlando, FL USA

[3] Winship Canc Inst, Dept Hematol Med Oncol, Atlanta, GA USA

[4] Piedmont Canc Inst, Atlanta, GA USA

[5] Ingalls Mem Hosp, Ingalls Canc Care, Harvey, ND USA

[6] Univ Maryland, Dept Med, Ctr Canc, Greenbaum Comprehens Canc Ctr, Baltimore, MD 21201 USA

[7] Seattle Genet Inc, Biostat, Bothell, WA USA

[8] Seattle Genet Inc, Clin Res, Bothell, WA USA

[9] H Lee Moffitt Canc Ctr & Res Inst, Dept Breast Oncol, Tampa, FL USA

来源：

ANNALS OF ONCOLOGY | 2019年 / 30卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

196TiP

引用

页数：1

共 50 条

[1] SGNLVA-002: Single arm, open-label, phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer
Cortes, J.
Diab, S.
Basho, R. K.
Oliveira, M.
Pluard, T.
Alemany, C.
Brown-Glaberman, U.
Meisel, J.
Boni, V.
Sinha, R.
Garcia Estevez, L.
Ettl, J.
Kuemmel, S.
Manso Sanchez, L. M.
Moon, Y. W.
Villanueva Vazquez, R.
Wuerstlein, R.
Wang, Y.
Wang, Z.
Han, H.
ANNALS OF ONCOLOGY, 2020, 31 : S393 - S393
[2] SGNLVA-002: Single-arm, open label phase lb/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer.
Han, Hyo S.
Alemany, Carlos A.
Brown-Glaberman, Ursa Abigail
Pluard, Timothy J.
Sinha, Rajni
Sterrenberg, Danielle
Albain, Kathy S.
Basho, Reva K.
Biggs, David
Boni, Valentina
Diab, Sami
Tsai, Michaela L.
Tkaczuk, Katherine Hanna
Wang, Yinghui
Wang, Zejing
Meisel, Jane Lowe
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[3] Phase 1b/2 study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer (SGNLVA-002, trial in progress)
Dillon, Patrick
Basho, Reva
Han, Hyo S.
Kolberg, Hans-Christian
Tkaczuk, Katherine
Zahrah, George
Gion, Maria
Voss, Herman
Meisel, Jane
Pluard, Timothy
Fox, Jenny
Oliveira, Mafalda
Brown-Glaberman, Ursa
Stringer-Reasor, Erica
Manso, Luis
Kuemmel, Sherko
Chen, Lin Chi
Wu, Sheng
Croft, Brandon
Boni, Valentina
CANCER RESEARCH, 2023, 83 (05)
[4] Open label phase 1b/2 study of ladiratuzumab vedotin in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancer
Han, Hyo
Diab, Sami
Alemany, Carlos
Basho, Reva
Brown-Glaberman, Ursa
Meisel, Jane
Pluard, Timothy
Cortes, Javier
Dillon, Patrick
Ettl, Johannes
Kuemmel, Sherko
Sanchez, Luis Manso
Oliveira, Mafalda
O'Shaughnessy, Joyce
Papish, Steven
Sinha, Rajni
Sterrenberg, Danielle
Stringer-Reasor, Erica
Tsai, Michaela
Vazquez, Rafael Villanueva
Wuerstlein, Rachel
Wang, Yinghui
Wang, Zejing
Boni, Valentina
CANCER RESEARCH, 2020, 80 (04)
[5] Phase 1b/2 study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer (SGNLVA-002, trial in progress)
Meisel, Jane Lowe
Pluard, Timothy J.
Vinayak, Shaveta
Stringer-Reasor, Erica Michelle
Brown-Glaberman, Ursa
Dillon, Patrick Michael
Basho, Reva K.
Varadarajan, Ramya
O'Shaughnessy, Joyce
Han, Hyo S.
Sinha, Rajni
Fox, Jenny R.
Villanueva, Rafael
Chen, Lin Chi
Wu, Sheng
Li, Hong
Tran, Sinhan
Manso, Luis
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[6] Open-label, phase II study of ladiratuzumab vedotin (LV) for unresectable locally advanced or metastatic solid tumors
Arkenau, H-T.
Guthrie, T.
Mekhail, T.
Cortinovis, D.
Antonuzzo, L.
Bruce, J. Y.
Gabrail, N.
Anderson, I.
Oh, S. C.
Oh, S. Y.
Nott, L.
Shah, M. A.
Sanborn, R. E.
Oh, D-Y.
Cho, J. Y.
Lin, C-C.
Lee, A.
Wang, Y.
Wang, Z.
Sher, A.
ANNALS OF ONCOLOGY, 2021, 32 : S671 - S672
[7] Phase I/II study of pembrolizumab in combination with oral binimetinib in patients with unresectable locally advanced or metastatic triple-negative breast cancer
Chumsri, Saranya
Larson, Joseph J.
Tenner, Kathleen S.
He, Jun
Polley, Mei-Yin
Weidner, Morgan T.
Arnold, Amanda N.
Haley, Dana
Advani, Pooja
Sideras, Kostandinos
Moreno-Aspitia, Alvaro
Perez, Edith A.
Knutson, Keith L.
CANCER RESEARCH, 2023, 83 (05)
[8] Phase I/II study of pembrolizumab in combination with oral binimetinib in patients with unresectable locally advanced or metastatic triple-negative breast cancer
Chumsri, Saranya
Larson, Joseph
Adams, Daniel
Tenner, Kathleen
Tang, Cha-Mei
Weidner, Morgan
Arnold, Amanda
Haley, Dana
Advani, Pooja
Sideras, Kostandinos
Moreno-Aspitia, Alvaro
Perez, Edith
Knutson, Keith
CANCER RESEARCH, 2024, 84 (09)
[9] Phase I results of the phase I/II study of pembrolizumab in combination with binimetinib in patients with unresectable locally advanced or metastatic triple-negative breast cancer
Chumsri, Saranya
Polley, Mei-Yin
Mathur, Pulkit
Reis, Aline
Tenner, Kathleen S.
Weidner, Morgan
Advani, Pooja
Moreno-Aspitia, Alvaro
Perez, Edith A.
Knutson, Keith L.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05)
[10] Peripheral blood biomarkers in Phase II study of pembrolizumab in combination with oral binimetinib in patients with unresectable locally advanced or metastatic triple-negative breast cancer
Chumsri, Saranya
Larson, Joseph J.
Adams, Daniel L.
Tenner, Kathleen S.
Tang, Cha-Mei
Weidner, Morgan T.
Arnold, Amanda N.
Haley, Dana L.
Advani, Pooja
Sideras, Kostandinos
Moreno-aspitia, Alvaro
Perez, Edith A.
Knutson, Keith L.
CANCER RESEARCH, 2023, 83 (07)

← 1 2 3 4 5 →